NVCR Earnings & Financial Statements
NovoCure Limited
$14.17
-$0.49(-3.34%)
48
Overall
60
Value
40
Tech
44
Quality
Market Cap
$1.71B
Volume
284.38K
52W Range
$9.82 - $21.45
Target Price
$27.14
NVCR earnings and financial statements: NovoCure Limited's income statement, balance sheet and cash flow statement, annual and quarterly.
NVCR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $655.35M | $605.22M | $509.34M | $537.84M | $535.03M |
| Cost of revenue | $166.88M | $137.18M | $128.28M | $114.87M | $1.04M |
| Operating income | -$153.80M | -$170.50M | -$232.87M | -$89.52M | -$44.33M |
| EBITDA | -$162.41M | -$184.91M | -$244.99M | -$69.42M | -$38.38M |
| Net income | -$136.23M | -$168.63M | -$207.04M | -$92.53M | -$58.35M |
| EPS (diluted) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $804.33M | $1.24B | $1.15B | $1.19B | $1.14B |
| Total liabilities | $463.86M | $880.61M | $783.63M | $750.48M | $729.00M |
| Shareholders’ equity | $340.47M | $360.18M | $362.50M | $441.17M | $410.49M |
| Cash and equivalents | $93.55M | $163.77M | $240.82M | $115.33M | $208.80M |
| Long-term debt | $236.69M | $117.27M | $596.24M | $584.27M | $575.21M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$49.03M | -$26.37M | -$73.34M | $30.79M | $82.76M |
| Capital expenditure | -$26.65M | -$42.85M | -$27.09M | -$21.36M | -$24.17M |
| Free cash flow | -$75.68M | -$69.22M | -$100.43M | $9.43M | $58.59M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVCR | $14.17 | -3.3% | 284.38K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |